Supriya Lifescience Stock Screener | Share Price & Fundamental Analysis
SUPRIYA
Pharmaceuticals
Share Price NSE
₹677.95
▼
-6.70 (-0.98%)
Share Price BSE
₹677.25
▼
-7.50 (-1.10%)
Track Supriya Lifescience share price live with TickJournal's free stock screener.
Analyze Supriya Lifescience share price history trends and compare 52-week high low
levels.
Calculate SUPRIYA stock fair value using fundamental analysis and view live share price charts.
Determine Supriya Lifescience share intrinsic value and compare it with current SUPRIYA share price.
Record your Supriya Lifescience trades in TickJournal's free trading journal and track your portfolio performance.
Supriya Lifescience Market Cap
₹5,479.67 Cr.
SUPRIYA P/E Ratio (TTM)
29.75
EPS (TTM)
₹23.35
Dividend Yield
0.15%
Debt to Equity
0.01
SUPRIYA 52 Week High
₹802.65
Supriya Lifescience 52 Week Low
₹589.75
Operating Margin
36.00%
Profit Margin
24.77%
SUPRIYA Revenue (TTM)
₹747.00
EBITDA
₹275.00
Net Income
₹185.00
Total Assets
₹1,112.00
Total Equity
₹997.00
Supriya Lifescience Share Price History - Stock Screener Chart
Screen SUPRIYA historical share price movements with interactive charts. Analyze price trends and patterns.
Supriya Lifescience Company Profile - Fundamental Screener
Screen Supriya Lifescience company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for SUPRIYA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE07RO01027
Supriya Lifescience Balance Sheet Screener
Screen SUPRIYA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,112 | 921 | 820 | 735 | 446 | 336 | 253 | 245 | 241 | 231 |
| Current Assets | 437 | 398 | 465 | 498 | 266 | 196 | 133 | 120 | 115 | 129 |
| Fixed Assets | 453 | 310 | 262 | 190 | 100 | 99 | 85 | 91 | 89 | 76 |
| Liabilities | ||||||||||
| Total Liabilities | 1,112 | 921 | 820 | 735 | 446 | 336 | 253 | 245 | 241 | 231 |
| Current Liabilities | 33 | 29 | 25 | 19 | 31 | 32 | 24 | 45 | 51 | 39 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 997 | 815 | 700 | 616 | 269 | 149 | 94 | 55 | 46 | 42 |
| Share Capital | 16 | 16 | 16 | 16 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves & Surplus | 981 | 799 | 683 | 600 | 254 | 134 | 79 | 40 | 31 | 26 |
Supriya Lifescience Income Statement Screener - Profit & Revenue Analysis
Screen Supriya Lifescience income statement and profit fundamentals.
Analyze SUPRIYA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Supriya Lifescience share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 747 | 706 | 581 | 470 | 538 | 396 | 323 | 286 | 222 | 191 | 172 | 140 |
| Expenses | 472 | 436 | 397 | 332 | 316 | 218 | 213 | 213 | 191 | 166 | 150 | 121 |
| EBITDA | 275 | 271 | 184 | 138 | 222 | 178 | 110 | 73 | 31 | 25 | 22 | 20 |
| Operating Profit % | 36.00% | 37.00% | 30.00% | 28.00% | 40.00% | 44.00% | 32.00% | 23.00% | 10.00% | 9.00% | 12.00% | 12.00% |
| Depreciation | 26 | 20 | 16 | 12 | 10 | 7 | 6 | 5 | 5 | 5 | 4 | 3 |
| Interest | 2 | 2 | 2 | 3 | 4 | 4 | 7 | 10 | 11 | 12 | 10 | 7 |
| Profit Before Tax | 247 | 249 | 166 | 124 | 207 | 167 | 96 | 57 | 15 | 8 | 8 | 10 |
| Tax | 54 | 61 | 47 | 34 | 55 | 44 | 23 | 18 | 6 | 2 | 2 | 2 |
| Net Profit | 185 | 188 | 119 | 90 | 152 | 124 | 73 | 39 | 9 | 6 | 6 | 8 |
| EPS | 23.00 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 | 10.02 | 5.39 | 1.19 | 3.87 | 3.89 | 16.82 |
Supriya Lifescience Cash Flow Screener - Liquidity Fundamentals
Screen SUPRIYA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 165 | 113 | 64 | 49 | 76 | 117 | 49 | 28 | 27 | 14 |
| Investing Activities | -152 | -174 | -124 | -60 | -47 | -25 | 5 | -5 | -27 | -33 |
| Financing Activities | -8 | -22 | -10 | 150 | -15 | -29 | -50 | -20 | -2 | 21 |
| Net Cash Flow | 4 | -83 | -70 | 139 | 15 | 62 | 4 | 3 | -2 | 2 |
Supriya Lifescience Shareholding Pattern Screener
See Supriya Lifescience shareholding pattern with promoter, FII, and DII holdings.
Check Supriya Lifescience promoter holding and ownership changes for SUPRIYA on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% |
| FII Holding | 7.19% | 6.78% | 5.46% | 5.20% | 5.36% | 4.95% | 6.03% | 6.52% |
| DII Holding | 4.26% | 4.86% | 5.22% | 5.01% | 5.30% | 5.48% | 5.45% | 4.92% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.40% | 16.39% | 16.77% | 16.66% | 17.06% | 17.19% | 0.00% | 16.28% |
| Other Holding | 3.85% | 3.67% | 4.25% | 4.83% | 3.98% | 4.08% | 20.23% | 3.98% |
| Shareholder Count | 91,051 | 91,928 | 87,912 | 85,099 | 87,980 | 89,621 | 85,328 | 89,394 |
Supriya Lifescience Share Dividend Screener - Share Yield Analysis
Check Supriya Lifescience dividend history with payout and yield data.
View Supriya Lifescience dividend details including ex-dates and amounts for SUPRIYA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.15% |
| 2024-March | ₹0.80 | 0.11% |
| 2023-March | ₹0.60 | 0.18% |
| 2022-March | ₹0.60 | 0.32% |
| 2021-March | ₹0.54 | 0.11% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Supriya Lifescience Stock Index Membership
See which indices include Supriya Lifescience stock.
Check SUPRIYA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Supriya Lifescience Market Events Screener - Corporate Actions
Get Supriya Lifescience corporate actions including splits, bonuses, and buybacks.
Check Supriya Lifescience stock events that may affect SUPRIYA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 1.00 /share | -11.70% | ||
| Dividend | ₹ 0.60 /share | 13.53% | ||
| Dividend | ₹ 0.80 /share | 74.84% | ||
| Annual General Meeting | NA | -6.20% | ||
| Dividend | ₹ 0.60 /share | -0.06% | ||
| Annual General Meeting | NA | 11.37% | ||
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 0.36% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -6.66% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -0.96% |
| 2025-05-27 | 2025-05-27 | Quarterly Result Announcement | NA | 5.82% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | 9.11% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -1.41% |
Supriya Lifescience Competitors Screener - Peer Comparison
Screen SUPRIYA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 407,287 | 37.56 | 54,729 | 9.71% | 10,980 | 52.49 |
| Divis Laboratories | 163,754 | 66.27 | 9,712 | 18.67% | 2,191 | 48.87 |
| Torrent Pharmaceuticals | 138,018 | 64.55 | 11,539 | 6.99% | 1,911 | 59.36 |
| Cipla | 107,555 | 23.69 | 28,410 | 7.12% | 5,291 | 35.86 |
| Dr Reddys Laboratories | 105,839 | 19.26 | 33,741 | 16.73% | 5,725 | 58.24 |
| Lupin | 100,464 | 23.23 | 22,910 | 13.74% | 3,306 | 56.93 |
| Zydus Life Science | 91,034 | 18.43 | 23,511 | 18.55% | 4,615 | 51.32 |
| Mankind Pharma | 85,058 | 47.59 | 12,744 | 20.90% | 2,007 | 42.02 |
| Aurobindo Pharma | 66,537 | 19.29 | 32,346 | 9.43% | 3,484 | 45.13 |
| Alkem Laboratories | 64,595 | 29.06 | 13,458 | 3.70% | 2,216 | 36.02 |
Supriya Lifescience Company Announcements - News Screener
Screen SUPRIYA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Change in Directorate | View |
| 2026-02-16 | Financial Result Quarter Ended On December 31 2025 | View |
| 2026-02-16 | Board Meeting Outcome for Outcome Of Board Meeting Held On February 09 2026 | View |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-02-02 | Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025. | View |
| 2026-01-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-12-30 | Announcement under Regulation 30 (LODR)-Credit Rating | View |
| 2025-12-28 | Closure of Trading Window | View |
| 2025-11-26 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-12 | Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-11-12 | Board Meeting Outcome for Outcome Of Board Meeting Held On November 12 2025 | View |